Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX <=2%) hemophilia B patients

P. Rendo, Pfizer Inc, Collegeville, PA, United States

Blood. 2012;120((21):): Abstract No. 4628.
Study details